ACMG 2026: 3billion Takes GEBRA to the Global Stage

Rare disease series | 26. 03. 18

The American College of Medical Genetics and Genomics (ACMG) is the leading authority in medical genetics and genomics — a professional academic organization spanning clinical research, education, and policy advocacy. At its core, ACMG is dedicated to integrating genetics and genomics across modern medicine, publishing essential guidelines for the medical genetics community including laboratory technical standards, clinical practice guidelines, and professional competency criteria.

The ACMG Annual Clinical Genetics Meeting serves as a premier global platform, bringing together world-class experts, researchers, and clinicians in genomic medicine to share the latest research findings and technological innovations while building international collaborative networks. As medical genetics plays an increasingly pivotal role across all areas of healthcare, attending ACMG represents an invaluable opportunity to connect directly with the professionals shaping the field’s latest trends and standards.

This year’s ACMG Annual Meeting was held in Baltimore, USA, from March 10 to 14, 2026. Here’s a firsthand look at what 3billion experienced on the ground.

GEBRA at ACMG

3billion set up at Booth #516, and the spotlight was squarely on GEBRA — 3billion’s proprietary variant interpretation platform, purpose-built for rare disease diagnosis.

With ACMG gathering the world’s top medical genetics professionals under one roof, it was the perfect stage to introduce GEBRA to a global audience. GEBRA supports the entire post-variant-interpretation workflow — from evidence curation and ACMG criteria evaluation to review documentation — in one seamless pipeline, enabling consistent interpretation across reviewers. This comprehensive approach drew significant attention from attendees throughout the event.

It was a meaningful opportunity to engage directly with global experts and share the clinical value that GEBRA brings to the table.

From the Floor: Words from Our Team

“ACMG was massive in scale, and you could genuinely feel the energy of genetics professionals converging from all over the world. What really stood out to me was that during our live GEBRA demos at the booth, visitors weren’t just casually curious — many were asking very specific questions about how it could fit into their actual workflows. Having direct conversations with experts from so many different institutions reaffirmed that the problems GEBRA is designed to solve are real, shared challenges felt across the field. Being able to introduce 3billion’s technology on a global stage was an incredibly meaningful experience for me personally.”

— Keonmin Son, GEBRA Sales Lead

This year’s ACMG reaffirmed what we’ve believed all along: the challenges GEBRA addresses are not unique to any one institution — they are universal pain points shared by organizations worldwide.

Interested in learning more about GEBRA? Reach out to us through the button below.